0      0

eSymposia | Antibodies and Vaccines as Drugs for COVID-19


ek31-esym-session- Ison-Michael - Therapeutic Effect of Regdanvimab (CT‑P59) in Patients with Mild to Moderate Symptoms of SARS CoV 2 Infection


Jan 13, 2021 11:10am ‐ Jan 13, 2021 11:25am

Speaker(s):

You must be logged in and own this session in order to post comments.

Leo OzurumbaDwight
1/13/21 10:34 am

Good day Presenter. Kindly brief us on how the technology and technigue invloved in development of CT-P59 Regdanvimad differ from that used to develop the first 2 Antibody based drugs already approved by US FDA ? Why is it that many antibody based drugs can not tackle Covid-19 in Sarscov-2 infected patients with severe symptoms ? Kindly explore techniques to shut-dowwn ADE effect, and to be capacitated to overcome variants that are emerging. I am confident that your team engaged good technigue to purify and concentrate your eluted antibody from your assays to optimize it's power of neutralization of antigen challenge. This will enhance eventual product. It's good news to see studies like this on Ab drugs that strive to break new grounds fro good remedies. Good luck sir. I commend the effort of Celltrion Inc in Ab drug discovery. Warm regards. Leo Ozurumba-Dwight

Leo OzurumbaDwight
1/13/21 10:37 am

These are my questions and suggestions. Well done to this team. US EUA approval in first instance, will be your focus onto eventual post - EUA success. With the will, it is achievable. Warm regards sirs

Print Certificate
Completed on: token-completed_on
Print Transcript
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content